Imaging Mycobacterium tuberculosis in Mice with Reporter Enzyme Fluorescence
February 26th, 2018
8.4K views
We describe the optical imaging of mice infected with Mycobacterium tuberculosis (M. tuberculosis) using reporter enzyme fluorescence (REF). This protocol facilitates the sensitive and specific detection of M. tuberculosis in pre-clinical animal models for pathogenesis, therapeutics and vaccine research.
Overview
This article describes a protocol for optical imaging of mice infected with Mycobacterium tuberculosis (M. tuberculosis) using reporter enzyme fluorescence (REF). The method enables sensitive and specific detection of M. tuberculosis in pre-clinical models, aiding research in pathogenesis, therapeutics, and vaccine development.
Key Study Components
Area of Science
- Neuroscience
- Infectious Diseases
- Imaging Techniques
Background
- M. tuberculosis is a major global health concern.
- Understanding its virulence mechanisms is critical for developing therapeutics.
- Imaging techniques can enhance the study of host-pathogen interactions.
- REF allows for longitudinal studies in the same group of animals.
Purpose of Study
- To facilitate the detection of M. tuberculosis in animal models.
- To study the progression of infection over time.
- To improve the statistical power of pre-clinical studies.
Methods Used
- Preparation of M. tuberculosis cultures and inoculation of mice.
- Use of a nebulizer for delivering the inoculum to the animals.
- Imaging using REF to visualize infection progression.
- Analysis of lung tissue to quantify bacterial load.
Main Results
- Fluorescence increased from week two to week six in infected mice.
- Control mice showed a slight drop in signal due to body mass increase.
- 3D FLIT reconstruction provided high-quality imaging results.
- CFU scores were used to measure infection severity.
Conclusions
- REF imaging is a valuable tool for studying M. tuberculosis.
- The method allows for repeated imaging of the same subjects.
- It enhances understanding of infection dynamics and treatment efficacy.
Frequently Asked Questions
What is REF imaging?
REF imaging is a technique that uses fluorescent substrates to visualize the presence of specific bacteria, such as M. tuberculosis, in live animals.
Why is it important to use the same group of animals for imaging?
Using the same group of animals reduces variability and increases the statistical power of the study.
How is the inoculum prepared for the mice?
The inoculum is prepared by culturing M. tuberculosis, pelleting the bacteria, and suspending them in saline before nebulization.
What safety precautions are taken during the experiment?
All procedures involving infectious materials are conducted in biosafety cabinets, and proper waste disposal methods are followed.
How is the severity of infection measured?
The severity of infection is measured using colony-forming units (CFU) from lung tissue homogenates.
What are the advantages of using REF imaging?
REF imaging allows for sensitive detection, longitudinal studies, and improved understanding of host-pathogen interactions.
Executive Industry Relevance
Reporter enzyme fluorescence (REF) enables longitudinal imaging of Mycobacterium tuberculosis infection in mice, reducing animal use and increasing statistical power in preclinical studies. This approach supports target validation and therapeutic efficacy testing by providing quantitative, real-time bacterial burden data without requiring recombinant strains. The method enhances mechanistic de-risking in tuberculosis drug discovery by allowing repeated measurements in the same cohort, improving predictive confidence in lead compound evaluation.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of virulence mechanisms and host-pathogen interactions through non-invasive, repeated imaging of M. tuberculosis in vivo.
- Operational Value: Eliminates need for terminal sampling at each timepoint, preserving animal cohorts for longitudinal analysis.
- Predictive Value: Supports target confidence by correlating fluorescence signal with CFU-derived bacterial load across infection stages.
Screening & Assay Development
- Scientific Value: Provides a quantitative fluorescence readout proportional to bacterial burden, enabling dose-response assessment of antibiotic candidates.
- Operational Value: Uses a single FRET substrate with emission at 800 nm for deep-tissue imaging, standardizing detection across studies.
- <Scalability: Compatible with high-throughput imaging platforms due to substrate specificity and catalytic signal amplification.
Translational & Preclinical Research
- Translational Continuity: Bridges in vitro target engagement with in vivo efficacy by tracking bacterial clearance in lungs over time.
- Mechanistic De-risking: Allows observation of infection dynamics and treatment response without confounding variables from cohort variability.
- Predictive Confidence: Increases statistical power by enabling more data points per animal, reducing group sizes needed for significance.
Pipeline & Workflow Integration
REF imaging fits within the discovery continuum from target validation through lead optimization to preclinical efficacy, supporting iterative design-make-test cycles in tuberculosis drug development.
- Discovery Biology: Facilitates hypothesis testing of virulence factors and host immune responses via longitudinal bacterial tracking.
- Screening: Enables assay-ready readouts for compound libraries using fluorescence intensity as a proxy for bacterial viability.
- Analytics: Generates quantitative longitudinal datasets suitable for pharmacokinetic/pharmacodynamic modeling and efficacy ranking.
- Translational Research: Supports biomarker alignment by linking fluorescence signal to histopathological and CFU endpoints.
- Enterprise Reuse: Establishes a reusable imaging platform applicable to other bacterial pathogens expressing BlaC or similar enzymes.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity by enabling direct visualization of bacterial load dynamics in intact tissues.
- Operational Value: Standardizes longitudinal monitoring through repeatable substrate administration and imaging protocols.
- Strategic Value: Improves go/no-go decisions by providing early, quantitative efficacy signals in vivo.
- Portfolio Impact: De-risks advancement candidates by increasing confidence in target-mediated antibacterial effects.
Implementation Considerations
- Requires expertise in biosafety level 3 procedures for M. tuberculosis handling and aerosol infection.
- Depends on optical imaging systems capable of near-infrared fluorescence detection (780–840 nm emission).
- Necessitates standardization of substrate dosing, anesthesia, and imaging timing across longitudinal sessions.
- Involves validation of fluorescence signal against CFU and histopathological endpoints for quantitative accuracy.
- Limited to pathogens expressing BlaC or compatible enzymes; not broadly applicable without reporter engineering.
Biopharma FAQs
Why does longitudinal imaging with REF improve target validation?
Longitudinal REF imaging allows repeated measurement of bacterial burden in the same animal cohort, reducing variability and increasing statistical power for assessing target engagement and therapeutic efficacy over time.
How does isolating the bacterial signal via REF substrate administration support discovery pipeline decisions?
Administering the REF substrate enables specific detection of M. tuberculosis via BlaC enzyme activity, producing a quantitative signal that correlates with CFU and supports go/no-go decisions in lead optimization.
What quantitative measurements does REF enable for evaluating antibiotic efficacy?
REF provides longitudinal fluorescence intensity measurements that reflect changes in bacterial load, allowing assessment of dose-dependent and time-dependent antibiotic effects in vivo.
Why are replication requirements important for cross-functional collaboration in REF-based studies?
Replication across animals and timepoints ensures data reliability, enabling consistent interpretation between discovery, preclinical, and translational teams evaluating host-pathogen dynamics.
What statistical analysis capabilities are needed before implementing REF in drug discovery workflows?
Teams require longitudinal data analysis methods to model fluorescence trends over time, correlate with CFU endpoints, and assess significance of treatment effects across imaging sessions.
